Takeshi Shimamura

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +11

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Esra A. Akbay, Shohei Koyama, Julián Carretero et al. · Cancer Discovery · 2013 · 1.2K citations · Full text

Medicine, Immunology, Oncology +17

LKB1 modulates lung cancer differentiation and metastasis

Hongbin Ji, Matthew R. Ramsey, D. Neil Hayes et al. · Nature · 2007 · 1.1K citations

Medicine, Cancer Biology, Oncology +11

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale et al. · Cancer Research · 2007 · 718 citations · Full text

Medicine, Oncology, Pharmacology +13

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li et al. · Cancer Research · 2016 · 630 citations · Full text

Medicine, Immunology, Oncology +17